Andrew Kellett is Associate Professor of Inorganic and Medicinal Chemistry in the School of Chemical Sciences at Dublin City University, Ireland. He leads a large multidisciplinary research group based at the National Institute for Cellular Biotechnology and Nano-Bioanalytical Research Facility. Over the past number of years he has established a critical mass of expertise in the areas of metallodrug development and in artificial gene editing. His research intersects materials science and chemical biology.
Nucleic Acid Interactions and Click Chemistry
Dr Kellett’s group focus on the development of hybrid gene editing therapeutics using ‘click chemistry’. These bioactive materials are analysed using a wide array of chemical biology methods including absorbance, fluorescence, circular dichroism, and thermal stabilisation (amongst others) to uncover new metallodrug binding properties and nucleotide binding specificity.
DNA Damage and Repair
The Kellett group are also focused on the development of new copper-based materials that mediate DNA damage through the production of reactive oxygen species (ROS). These materials find applications in both genome engineering and medicinal chemistry. The group has expertise in techniques including electrophoresis, on-chip microfluidics, flow cytometry, confocal microscopy, fluorescence spectroscopy and qPCR for the detection of DNA and cellular damage.
Chemotherapeutic Drug Development
A range of cancer cell biology, molecular biological, and microscopy techniques are applied to probe the mechanistic activity and redox-targeting properties of metallodrug leads developed within the group. We primarily focus on intracellular ROS production, organelle targeting, genotoxicity and the origin and activation of cell death pathways that include apoptosis and autophagy.
Dr Kellett is coordinator of the Horizon 2020 Marie Skłodowska-Curie Innovative Training Network (ITN) ClickGene and the Science Foundation Ireland (SFI) Career Development Award Polynuclear Platinum(II) Biomaterials (PPtBio) for Antisense Therapeutic Application and Detection of Human Genetic Disease. He has numerous collaborations with high profile international academic and industry partners.
The Kellett group have authored more than 40 papers in peer reviewed scientific journals and publish their work in premier journals including Nucleic Acids Research, Chemical Communications, Journal of Medicinal Chemistry, Inorganic Chemistry, Chemistry – A European Journal, and Dalton Transactions. Prof. Kellett also holds several patents in the areas of metallodrug design and therapeutic application.
Dr Kellett was recently awarded “Ireland’s Champion of EU Research” by Enterprise Ireland in recognition of his leadership of the ClickGene Horizon 2020 Programme.
+353 (0) 91 495833